Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015 (2015), Article ID 642046, 8 pages
Research Article

The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients

1Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China
2Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China
3Department of Thyroid and Breast Surgery, West China Hospital, Sichuan University, Chengdu 610041, China

Received 20 May 2015; Revised 13 July 2015; Accepted 14 July 2015

Academic Editor: Diego Russo

Copyright © 2015 Li-Bo Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The mutation is commonly found in papillary thyroid cancers (PTCs) at different frequencies in different regions. However, the association between the mutation and clinicopathological features in Chinese PTC patients is unknown. A total of 543 Chinese patients with histologically confirmed PTC were enrolled in this study. For the BRAF mutation assay, the target fragments were amplified and sequenced with an ABI 3500 gene analyzer. In 170 of 543 samples (31.3%), the mutation was detected. In the bivariate analysis, the mutation showed an association with bilaterality, tumor size, extrathyroidal invasion, and lymph node metastases (LNM). However, in the multivariate analysis, the mutation was positively related to only tumor size (>1 cm) and extrathyroidal invasion. In addition, the multivariate analysis also showed that the age at diagnosis (<45 y) and tumor size (>1 cm) were independent predictors for LNM. In this study, the mutation is positively associated with worse prognostic factors, including larger tumor size and the tumor extending to the thyroid capsule or extrathyroidal region; however, it is not an independent predictor for LNM.